Trial to Assess Safety, Efficacy, Tolerability and Immunogenicity of Influenza Virus Vaccine, Liquid Formulation (CAIV-T), Administered Concomitantly With a Combination Live, Attenuated, Mumps, Measles, and Rubella Vaccine in Healthy Children Aged 11 - 24 Months
Clinical trial NCT00192166 · COMPLETED
Trial details
- NCT number
- NCT00192166
- Sponsor
- MedImmune LLC
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2002-10-01
- Primary completion
- 2003-03-01
- Enrollment
- 1200
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.